Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the …
Jetzt den vollständigen Artikel lesen